Schering antifungal
Executive Summary
SCH-39304 has entered Phase II trials for treatment of serious systemic fungal infections including Candida, cryptococcal meningitis, Aspergillus and Trichophyton - infections frequently occurring in cancer patients undergoing chemotherapy as well as AIDS patients. The product will likely compete in the U.S. market against Pfizer's Diflucan (fluconazole), for which an NDA is currently pending. SCH-39304 is licensed from the Japanese firm Sumitomo, which has retained marketing rights for Japan and certain Far East countries....